Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMIX Autonomix Medical	$1.25 -0.8%	$1.70	$1.14 ▼ $42.40	$3.50M	-3.46	347,168 shs	26,427 shs
NUWE Nuwellis	$0.26 +1.1%	$0.73	$0.21 ▼ $6.61	$1.12M	0.48	3.41 million shs	1.62 million shs
NVIVQ InVivo Therapeutics	$0.37	$0.37	$0.00 ▼ $0.00	N/A	N/A	N/A	N/A
QNRX Quoin Pharmaceuticals	$9.73 +4.0%	$7.81	$5.01 ▼ $54.95	$5.51M	1.44	136,616 shs	16,152 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMIX Autonomix Medical	-0.79%	+4.17%	-28.16%	-31.69%	-93.59%
NUWE Nuwellis	+1.14%	-7.49%	-71.03%	-73.54%	-94.85%
NVIVQ InVivo Therapeutics	0.00%	0.00%	0.00%	0.00%	+36,999,900.00%
QNRX Quoin Pharmaceuticals	+3.95%	+15.83%	-1.32%	+14.97%	-52.88%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMIX Autonomix Medical	2.6123 of 5 stars	3.5	2.0	0.0	0.0	1.9	1.7	1.3
NUWE Nuwellis	3.3582 of 5 stars	3.5	5.0	0.0	0.0	3.3	0.0	1.3
NVIVQ InVivo Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
QNRX Quoin Pharmaceuticals	1.2583 of 5 stars	0.0	5.0	0.0	0.0	2.1	0.0	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMIX Autonomix Medical	3.00	Buy	$16.50	1,220.00% Upside
NUWE Nuwellis	3.00	Buy	$17.00	6,489.15% Upside
NVIVQ InVivo Therapeutics	0.00	N/A	N/A	N/A
QNRX Quoin Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest NVIVQ, QNRX, AMIX, and NUWE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
5/13/2025	NUWE Nuwellis	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/29/2025	AMIX Autonomix Medical	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$5.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMIX Autonomix Medical	N/A	N/A	N/A	N/A	$3.29 per share	N/A
NUWE Nuwellis	$8.74M	0.13	N/A	N/A	$1.49 per share	0.17
NVIVQ InVivo Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
QNRX Quoin Pharmaceuticals	N/A	N/A	N/A	N/A	$35.47 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMIX Autonomix Medical	-$11.41M	-$7.47	N/A	N/A	N/A	N/A	-174.70%	-133.35%	N/A
NUWE Nuwellis	-$11.16M	-$18.24	N/A	N/A	N/A	-112.09%	-655.31%	-141.83%	8/12/2025 (Estimated)
NVIVQ InVivo Therapeutics	-$10.49M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
QNRX Quoin Pharmaceuticals	-$8.96M	-$48.81	N/A	N/A	N/A	N/A	-148.97%	-77.23%	8/14/2025 (Estimated)

Latest NVIVQ, QNRX, AMIX, and NUWE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/29/2025	Q4 2025	AMIX Autonomix Medical	N/A	-$0.74	N/A	-$0.74	N/A	N/A
5/13/2025	Q1 2025	NUWE Nuwellis	-$0.45	-$0.69	-$0.24	-$0.69	$2.50 million	$1.90 million
5/13/2025	Q1 2025	QNRX Quoin Pharmaceuticals	-$3.85	-$6.50	-$2.65	-$6.50	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMIX Autonomix Medical	N/A	N/A	N/A	N/A	N/A
NUWE Nuwellis	N/A	N/A	N/A	N/A	N/A
NVIVQ InVivo Therapeutics	N/A	N/A	N/A	N/A	N/A
QNRX Quoin Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMIX Autonomix Medical	N/A	5.63	5.63
NUWE Nuwellis	N/A	2.23	1.59
NVIVQ InVivo Therapeutics	N/A	N/A	N/A
QNRX Quoin Pharmaceuticals	N/A	2.57	2.57

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMIX Autonomix Medical	10.78%
NUWE Nuwellis	3.13%
NVIVQ InVivo Therapeutics	12.32%
QNRX Quoin Pharmaceuticals	8.63%

Insider Ownership

Company	Insider Ownership
AMIX Autonomix Medical	32.40%
NUWE Nuwellis	1.60%
NVIVQ InVivo Therapeutics	2.45%
QNRX Quoin Pharmaceuticals	3.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMIX Autonomix Medical	1	2.78 million	1.88 million	N/A
NUWE Nuwellis	70	4.37 million	4.30 million	Not Optionable
NVIVQ InVivo Therapeutics	6	N/A	N/A	N/A
QNRX Quoin Pharmaceuticals	4	590,000	566,000	Not Optionable

NVIVQ, QNRX, AMIX, and NUWE Headlines

Recent News About These Companies

QNRX - Quoin Pharmaceuticals Ltd ADR Executives - Morningstar

June 26 at 12:45 PM | morningstar.comM

Quoin Pharmaceuticals Releases New NETHERTON NOW Video Featuring Professor Jemima Mellerio, International Expert in Genetic Skin Diseases

June 26 at 12:45 PM | finance.yahoo.com

Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome - Yahoo Finance

June 25 at 11:23 PM | finance.yahoo.com

Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome

June 24 at 5:28 PM | tmcnet.com

Quoin Pharmaceuticals, Ltd. (QNRX) - Yahoo Finance

June 24 at 5:28 PM | finance.yahoo.com

QNRX: With FDA Clearance to Initiate 2nd NS Whole Body Study for QRX003, Clinical Activities Expand Further

May 29, 2025 | finance.yahoo.com

Quoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study

May 22, 2025 | manilatimes.netM

Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome

May 20, 2025 | globenewswire.com

Quoin reports progress in pediatric skin disorder study

May 15, 2025 | investing.com

Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study

May 14, 2025 | globenewswire.com

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2025 Financial Results

May 14, 2025 | manilatimes.netM

A Peek at Quoin Pharmaceuticals's Future Earnings

May 12, 2025 | benzinga.com

Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

May 1, 2025 | finanznachrichten.de

Quoin Pharmaceuticals regains Nasdaq compliance with bid price

May 1, 2025 | investing.com

Quoin Pharmaceuticals regains Nasdaq compliance

April 30, 2025 | msn.com

Quoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

April 30, 2025 | globenewswire.com

Why Quoin Pharmaceuticals, Ltd.’s (QNRX) Stock Is Down 13.50%

April 10, 2025 | aaii.comA

Quoin Pharmaceuticals Releases Second Episode of its “Living with Netherton” Series, as part of its ongoing NETHERTON NOW awareness campaign

April 10, 2025 | globenewswire.com

Quoin Pharmaceuticals Ltd – ADR trading halted, news pending

April 9, 2025 | markets.businessinsider.com

Quoin Pharmaceuticals announces ADS ratio change to meet Nasdaq requirements

April 6, 2025 | uk.investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVIVQ, QNRX, AMIX, and NUWE Company Descriptions

Autonomix Medical NASDAQ:AMIX

$1.25 -0.01 (-0.79%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$1.34 +0.09 (+6.80%)

As of 08:27 AM Eastern

Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.

Nuwellis NASDAQ:NUWE

$0.26 +0.00 (+1.14%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$0.25 -0.01 (-3.10%)

As of 08:25 AM Eastern

Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company offers Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors in Austria, Belarus, Brazil, Colombia, the Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Panama, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.

InVivo Therapeutics NASDAQ:NVIVQ

$0.37 0.00 (0.00%)

As of 07/26/2024

InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord to treat acute SCI. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.

Quoin Pharmaceuticals NASDAQ:QNRX

$9.73 +0.37 (+3.95%)

Closing price 06/26/2025 03:59 PM Eastern

Extended Trading

$9.29 -0.44 (-4.52%)

As of 08:00 AM Eastern

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time